Rat and Rabbit Plasma Distribution of Free and Chylomicron-Associated BIRT 377, a Novel Small Molecule Antagonist of LFA-1-Mediated Cell Adhesion |
| |
Authors: | Wasan Kishor M. Ramaswamy Manisha Holtorf Lorilynne Jayaraj Andrew A. Hauss David J. |
| |
Affiliation: | (1) Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada;(2) Department of Bioassay, Biogen Inc., Cambridge, Massachusetts;(3) Drug Metabolism & Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals Inc., Indianapolis, Indiana;(4) Eli Lilly, Indianapolis, Indiana |
| |
Abstract: | Purpose. The objectives of this study are to determine the plasma distribution of free and chylomicron-associated BIRT 377 within rats and rabbits.Methods. For the rat studies free and chylomicron-associated BIRT 377 was incubated in plasma from CD 1 non-fasted rats for 60 minutes at 37°C. Following incubation the plasma was separated into its lipoprotein and lipoprotein-deficient plasma (LPDP) fractions by three different methods and analyzed for BIRT 377 content by HPLC. For the rabbit studies New Zealand fasted white rabbits (3 kg; n = 4) were administered an intravenous dose of free BIRT 377 (1 mg/kg). Following administration, serial blood samples were obtained and the plasma was analyzed for BIRT 377. The plasma collected at the 0.083-h time point was separated into each of its lipoprotein fractions and analyzed for BIRT 377.Results. 37.8 ± 1.2% of the original drug amount incubated in rat plasma was recovered within the lipoprotein-rich fraction. 41.5 ± 0.4% of the original chylomicron-associated drug concentration incubated was recovered within the lipoprotein-rich fraction. The percentage of drug recovered within the TRL fraction was significantly greater following the incubation of chylomicron-associated BIRT 377 compared to free BIRT 377. In addition, BIRT 377 apparently follows a two-compartment pharmacokinetic model following single intravenous dose administration to rabbits.Conclusions. These findings suggest that plasma lipoprotein binding of BIRT 377 is evident and may be a factor in evaluating the pharmacological fate of this drug when administered to patients that exhibit changes in their plasma lipoprotein lipid. |
| |
Keywords: | lipid-based drug delivery lipoproteins hydrophobic drugs chylomicrons |
本文献已被 SpringerLink 等数据库收录! |
|